Celyad Outlines Key 2019 Priorities Including the Acceleration of the CYAD-01 Program in r/r AML and MDS
January 07, 2019 01:00 ET
|
Celyad SA
Lead candidate CYAD-01 continues to demonstrate encouraging clinical activity in THINK Phase 1 trial with a new complete response (CR) observed in patient with myelodysplastic syndrome (MDS)Key focus...
Celyad Presents Update on CYAD-01 Hematological Malignancies Clinical Program at 60th ASH Annual Meeting
December 04, 2018 01:45 ET
|
Celyad SA
CYAD-01 without preconditioning chemotherapy was well-tolerated and demonstrated anti-leukemic activity in five out of eight (62%) evaluable patients with relapsed or refractory (r/r) acute myeloid...
Celyad Doses First mCRC Patient in the Phase 1 alloSHRINK Trial Evaluating Non-Gene Edited Allogeneic CAR-T Candidate, CYAD-101
November 30, 2018 01:00 ET
|
Celyad SA
Topline data from alloSHRINK trial are expected in second half of 2019Company regains full development and commercialization rights to CYAD-101 from ONO Pharmaceutical for Japan, Korea and Taiwan ...
Celyad Announces Third Quarter 2018 Business Update
November 21, 2018 01:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, Nov. 21, 2018 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad to Participate at Upcoming Healthcare Conferences
November 15, 2018 01:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, Nov. 15, 2018 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad Presents Update on CYAD-01 Solid Tumor Clinical Program at the SITC 33rd Annual Meeting
November 09, 2018 12:45 ET
|
Celyad SA
Standalone CYAD-01 without preconditioning leads to disease stabilization in three out of 11 metastatic colorectal cancer (mCRC) patients in THINK Phase 1 trialInitial data from first dose cohort of...
Celyad to Present New CYAD-01 Data from THINK Study in Relapsed/Refractory Acute Myeloid Leukemia at 2018 ASH Annual Meeting
November 01, 2018 09:01 ET
|
Celyad SA
Oral presentation highlighting updated THINK study data evaluating CYAD-01 without preconditioning chemotherapy in relapsed or refractory (r/r) acute myeloid leukemia (AML)As of July 2018, three out...
Celyad to Present CYAD-01 Solid Tumor Clinical Updates and Pre-Clinical Pipeline Data at the 2018 SITC Annual Meeting
October 04, 2018 01:03 ET
|
Celyad SA
Celyad’s pipeline to be highlighted in oral and poster presentations at SITC 2018 MONT-SAINT-GUIBERT, Belgium, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ:...
Celyad Announces Exclusive Agreement for Horizon Discovery’s shRNA Platform to Develop Next-Generation Allogeneic CAR-T Therapies
October 04, 2018 01:00 ET
|
Celyad SA
In vivo study results to be presented at the 2018 SITC Annual Meeting MONT-SAINT-GUIBERT, Belgium, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a...
Transparency Notification of Victory Capital Management Inc.
September 28, 2018 01:00 ET
|
Celyad SA
(Article 14 of the Law of 2 May 2007) MONT-SAINT-GUIBERT, Belgium, Sept. 28, 2018 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD) a clinical-stage...